How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

118 results for

Quad Screen

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Quad Screen

Quad Screen Quad Screen Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Quad Screen Quad Screen Aka: Quad Screen , Aneuploidy (...) Screening , Triple Analyte Screen , Triple Screen , Antepartum Neural Tube Defect Screening , Antepartum Down Syndrome Screening , Second Trimester Quad Maternal Screen Panel II. Indication Congenital defect screening in low risk pregnancy III. Components: Tests comprising Quad Screen (AFP) Increased with s Decreased in and Trisomy 18 Human chorionic gonadotropin (Free bHCG) Increased in and decreased in Trisomy 18 (uE3) Decreased in and Trisomy 18 Inhibin A Increased in and normal in Trisomy 18 IV

2018 FP Notebook

2. Screening of fetal aneuploidies whereby non-invasive prenatal test (NIPT)

Screening of fetal aneuploidies whereby non-invasive prenatal test (NIPT) Dec2015 © EUnetHTA, 2015. Reproduction is authorised provided EUnetHTA is explicitly acknowledged 1 EUnetHTA Joint Action 3 WP4 Version 1.5, 23 rd February 2018 Rapid assessment of other technologies using the HTA Core Model ® for Rapid Relative Effectiveness Assessment SCREENING OF FETAL TRISOMIES 21, 18 AND 13 BY NONINVASIVE PRENATAL TESTING Project ID: OTCA03 Screening of fetal trisomies 21, 18 and 13 by noninvasive (...) Cunqueiro Hospital, Spain, who had undergone NIPT participated in the draft project plan consultation phase. Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 3 Consultation of the draft rapid assessment Manufacturers [v 1.2] (factual accuracy check) Sequenom Laboratories, San Diego, CA, USA Ariosa Diagnostics Inc./Roche Sequencing Solutions Inc., San Jose, California, USA Natera ® , San Carlos, CA, USA Premaitha Health

2018 EUnetHTA

3. Quad Screen

Quad Screen Quad Screen Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Quad Screen Quad Screen Aka: Quad Screen , Aneuploidy (...) Screening , Triple Analyte Screen , Triple Screen , Antepartum Neural Tube Defect Screening , Antepartum Down Syndrome Screening , Second Trimester Quad Maternal Screen Panel II. Indication Congenital defect screening in low risk pregnancy III. Components: Tests comprising Quad Screen (AFP) Increased with s Decreased in and Trisomy 18 Human chorionic gonadotropin (Free bHCG) Increased in and decreased in Trisomy 18 (uE3) Decreased in and Trisomy 18 Inhibin A Increased in and normal in Trisomy 18 IV

2015 FP Notebook

4. Prenatal Screening for Down Syndrome, Trisomy 18, and Open Neural Tube Defect

Prenatal Screening for Down Syndrome, Trisomy 18, and Open Neural Tube Defect Perinatal Services BC Obstetric Guideline: Prenatal Screening for Down Syndrome, Trisomy 18 and Open Neural Tube Defects Table of Contents EXECUTIVE SUMMARY ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 2 1? INTRODUCTION ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 3 SIPS, IPS, Quad, NIPT ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 3 Open Neural Tube Defects (ONTDs (...) screen result from IPS, SIPS, or Quad; b) Women who have a documented history of a previous child or fetus with Down syndrome, trisomy 18, or trisomy 13; c) Women whose risk of Down syndrome is equal to or greater than 1/300 based on the finding of ultrasound marker(s) and results of SIPS / IPS / Quad? 1 In order to ensure quality NT ultrasounds, every certified sonographer must annually perform a minimum number of ultrasounds? As such, pregnant women 30 years and older in Northern Health Authority

2014 British Columbia Perinatal Health Program

5. Clinical Evaluation of the IONA Test for Non-invasive Pre Natal Screening in Twin Pregnancies

information Ages Eligible for Study: 16 Years and older (Child, Adult, Older Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Currently pregnant with twin foetuses at time of entry to study Have had or are about to have a conventional screening test (combined/quad test, ultrasound scan or other NIPT) If identified as high risk, intend to undergo prenatal invasive diagnosis and/or undergoing invasive prenatal therapy such as laser treatment for TTTS where (...) Clinical Evaluation of the IONA Test for Non-invasive Pre Natal Screening in Twin Pregnancies Clinical Evaluation of the IONA Test for Non-invasive Pre Natal Screening in Twin Pregnancies - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2016 Clinical Trials

6. First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein A, free-β human chorionic gonadotrophin, placental growth factor and α-fetoprotein. (Abstract)

(first trimester quad) was assessed.For affected pregnancies, the median PlGF level was 0.622 MoM and median AFP 0.764 MoM. Adding PlGF and AFP improved the screening performance. At 3% FPR, DR increased by 4.4% from 83.8% to 88.2% using enhanced FTS; at 95% DR, FPR decreased by 8.3%, from 19.3% to 11.0%. At 3% FPR, DR using first trimester quad test was 76.4%.The performance of FTS can be enhanced by adding PlGF and AFP. Even without nuchal translucency, the test would perform well.© 2015 John Wiley (...) First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein A, free-β human chorionic gonadotrophin, placental growth factor and α-fetoprotein. The aim of this study was to assess the screening performance for Down syndrome using first trimester combined screening (FTS) and two additional markers, serum placental growth factor (PlGF) and α-fetoprotein (AFP).This is a retrospective case-control study of 137 pregnancies affected

2015 Prenatal diagnosis

7. Will a quadruple multiplexed point-of-care screening strategy for HIV-related co-infections be feasible and impact detection of new co-infections in at-risk populations? Results from cross-sectional studies. Full Text available with Trip Pro

Will a quadruple multiplexed point-of-care screening strategy for HIV-related co-infections be feasible and impact detection of new co-infections in at-risk populations? Results from cross-sectional studies. Multiplexed point-of-care (POC) devices can rapidly screen for HIV-related co-infections (eg, hepatitis C (HCV), hepatitis B (HBV), syphilis) in one patient visit, but global evidence for this approach remains limited. This study aimed to evaluate a multiplex POC testing strategy (...) to expedite screening for HIV-related co-infections in at-risk populations.A multiplex strategy was developed with two subsequent versions of an investigational device Miriad. It was evaluated in two non-comparable settings and populations in two countries for feasibility of conduct, detection of new infections, preference and accuracy. Version 1 was evaluated in 375 sexually transmitted disease clinic attendees in Mumbai, India; version 2 was evaluated in 119 injection drug users in Montreal

2014 BMJ open

8. AFP Maternal Screening

AFP Maternal Screening Second trimester maternal screening Produced by In partnership with User Top Links Menu Search User Top Links Search Second trimester maternal screening Also Known As Triple test Quad/quadruple test Formal Name Maternal Serum Screen This article was last reviewed on 19 February 2014. This article was last modified on 26 October 2018. At a Glance Why Get Tested? To assess the risk of a foetus having certain chromosomal abnormalities, such as or Edward’s syndrome (trisomy (...) 18). When To Get Tested? In most centres women will be offered between 11-13 weeks, although for some it may be carried out in the second trimester, usually between 14 and 20 weeks of . Sample Required? A blood sample taken from a vein in the arm. The results from the laboratory may be combined with the results from an ultrasound scan to improve the overall effectiveness of the screening test. Test Preparation Needed? None Looking for Test Results? On average it takes 7 working days for the blood

2012 Lab Tests Online UK

9. Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood

Other: Serum QUAD Assay for aneuploidy screening Other: Semiconductor MPSS NIPT assay using ccfDNA in maternal blood Other: Optical-based MPSS NIPT assay using ccfDNA in maternal blood Other: Harmony™ Test (Ariosa Diagnostics) Not Applicable Detailed Description: The present study is a real life comparative effectiveness study that will compare the performances and costs of several prenatal screening modalities for fetal aneuploidy (see interventions). Study Design Go to Layout table for study (...) : related topics: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Low Risk of aneuploidy Integrated prenatal screening for Down's syndrome (with follow-up fetal karyotype if positive); Serum QUAD Assay for aneuploidy screening; Semiconductor MPSS NIPT assay using ccfDNA in maternal blood; Optical-based MPSS NIPT assay using ccfDNA in maternal blood; Harmony™ Test (Ariosa Diagnostics) Other: Integrated prenatal screening for Down's syndrome Analysis of several serum

2013 Clinical Trials

10. First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA. (Abstract)

First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA. This study aimed to evaluate serum-only four-marker first trimester (1T-Quad) Down syndrome screening, alone or contingently to select 10-20% with highest risk for nuchal translucency (NT) or cell-free (cf)DNA.Stored maternal serum samples (-80 °C) from 90 pregnancies with fetal Down syndrome and 1607 controls were retrieved and measured for placental growth factor, α (...) -fetoprotein, pregnancy-associated plasma protein and free β-human chorionic gonadotropin. Samples were from singleton pregnancies (9-13 + 6 weeks), and NT was measured between 11 and 13 + 6 weeks. Markers were expressed in multiples of the normal median (MoM) for gestation. Gaussian models were fitted to the distribution of log MoMs by using observed parameters, standardized maternal age distribution (mean 27, SD 5.5) and published cfDNA results.The model-predicted detection rate (DR) for 1T-Quad was 74

2013 Prenatal diagnosis

11. Use of ethnic-specific medians for Hispanic patients reduces ethnic disparities in multiple marker screening. (Abstract)

Use of ethnic-specific medians for Hispanic patients reduces ethnic disparities in multiple marker screening. To estimate whether midtrimester maternal serum analyte concentrations differ between Caucasian and Hispanic women and whether using ethnic-specific medians affects quad screen performance.Caucasian and Hispanic patients with singletons who underwent maternal serum screening in our laboratory were identified. Alfa-fetoprotein (AFP), estriol, human chorionic gonadotrophin (hCG (...) was higher (P < 0.0001). Using composite medians, the screen-positive rate (SPR) for trisomy 21 was 5.39% in Caucasians and 3.29% in Hispanics. Ethnic-specific medians reduced this disparity: 4.76% in Caucasians and 4.05% in Hispanics. The SPR for neural tube defects with composite medians was 1.44% for Caucasians and 0.89% for Hispanics; with ethnic-specific medians, the SPR was 1.42% for Caucasians and 1.07% for Hispanics.Serum analyte concentrations differ between Caucasian and Hispanic gravidas. Use

2011 Prenatal diagnosis

12. Genome-Wide Sequencing for Unexplained Developmental Disabilities or Multiple Congenital Anomalies

Criteria 16 Literature Screening 18 Data Extraction 18 Evidence Synthesis 18 Critical Appraisal of Evidence 18 Results 20 Clinical Literature Search 20 Characteristics of Included Studies 21 Risk of Bias in the Included Studies 21 Diagnostic Yield 22 Clinical Utility 28 Ongoing Studies 30 Discussion 32 Conclusions 34 ECONOMIC EVIDENCE 35 Research Question 35 Methods 35 Economic Literature Search 35 Eligibility Criteria 35 Literature Screening 35 Data Extraction 36 Study Applicability and Limitations 36 (...) ). When testing is done on the proband alone, it is March 2020 Ontario Health Technology Assessment Series; Vol. 20: No. 11, pp. 1–178, March 2020 12 referred to as singleton testing. Other options for testing include duo or quad testing that assesses just one parent, a non-parent relative, or even siblings. Challenges of Genome-Wide Sequencing Whole exome and whole genome sequencing are promising technologies, yet there are limitations and challenges for their use in clinical practice. The analysis

2020 Health Quality Ontario

13. ASTRO/ESTRO Practice Recommendations for Risk-adapted Head and Neck Cancer Radiotherapy During the COVID-19 Pandemic

in the extent, duration, and characterisation of pandemic conditions across nations and regions. Decision-making within the context of continually evolving pandemic conditions is further challenged by the prolonged nature of a course of chemoradiation in the HNC population. Panellists also wished to address the conditions under which a SARS-CoV-2+ patient might be treated. As resources permit, clinicians should adhere to formal, pre-specified screening and viral testing algorithms for HNC patients, because (...) that response (latter does not add up to 100%). *Panellists called this schedule “quad shot” but the exact schedule can vary; the most common version is 3.7 Gy given twice daily for 2 days, repeated for 3 cycles. Table 2. Chemotherapy recommendations: standard, early pandemic and late pandemic approaches. Standard approach Scenario 1 Early Pandemic - risk mitigation Standard therapy: % endorsement Scenario 2 Late Pandemic - severe shortage of radiotherapy capacity Standard therapy: % endorsement 1

2020 American Society for Radiation Oncology

14. Prenatal Care

for certain high-risk populations (see Table 5). • Screening for aneuploidy and neural tube defects should be offered to all pregnant women. - Women at average risk of aneuploidy should be offered the integrated screen or prenatal risk quad screen (see Table 6). - Women at high risk of aneuploidy can be offered screening with cell-free DNA, plus separate neural tube defect screening with AFP (see Table 7 and Figure 1). Carrier status screening Table 5. First trimester screening for inherited disorders (...) at AVERAGE RISK of aneuploidy Both the integrated screen and the prenatal risk quad screen (PRS), which is often referred to as the “quadscreen, are reasonable options for estimating patient-specific risk for chromosome abnormalities (see Table 6). The integrated screen has a higher detection rate (96% vs. 81%) than the PRS (Malone 2005), but other factors such as timing, maternal preference, and availability may favor the PRS screen. Whichever screening test is used, the patient should be advised

2018 Kaiser Permanente Clinical Guidelines

15. Effects of early, computerized brief interventions on risky alcohol use and risky cannabis use among young people Full Text available with Trip Pro

and 25 years of age who were defined as risky consumers of alcohol or cannabis, or both. DATA COLLECTION AND ANALYSIS Two researchers independently screened titles and abstracts against the inclusion criteria. Two researchers independently assessed the full texts of all included articles. We used standard methodological procedures expected by the Campbell Collaboration. RESULTS We included 60 studies that had randomized 33,316 participants in this review. Study characteristics: The studies were (...) individuals from 17 countries indicates that high drug use is not related to more stringent policies ( ), suggesting the need to implement other methods to prevent risky alcohol or recreational drug use. For example, Roche and Freeman ( ) have illustrated the advantages of implementing screening and of brief, early interventions for young people with alcohol and drug problems. However, the effects of such interventions are unclear. 1.2 TRENDS AND CONSEQUENCES OF ALCOHOL AND CANNABIS USE AMONGST YOUNG

2017 Campbell Collaboration

16. Management of Pregnancy

. Implementation 18 IV. Guideline Work Group 19 V. Algorithm 20 A. Algorithm Key 21 B. Actions at Every Visit 21 C. Interventions by Weeks Gestation 21 D. Standard of Pregnancy Care 23 a. Additional Information on Actions at Every Visit 23 b. Screenings 24 c. Time Sensitive Care 28 d. Summary 28 VA/DoD Clinical Practice Guideline for the Management of Pregnancy March 2018 Page 4 of 147 VI. Routine Pregnancy Care 29 VII. Recommendations 33 A. Care Throughout Pregnancy 36 a. Routine Care During Pregnancy 36 b (...) . Nutrition 39 c. Screening 40 d. Education 43 B. One-time Interventions 44 a. Screening and Diagnostic Testing 44 b. Imaging 49 c. Preparing for Delivery 50 d. Postpartum Care 51 C. Referral 52 D. Special Considerations 55 a. High Risk for Preeclampsia 55 b. High Risk for Preterm Delivery 56 c. Over 44 Years of Age 57 d. History of Bariatric Surgery 58 Appendix A: Evidence Review Methodology 62 A. Developing the Scope and Key Questions 62 a. Population(s) 62 b. Interventions 62 c. Comparators 64 d

2018 VA/DoD Clinical Practice Guidelines

17. Treating Cough Due to Non-CF and CF Bronchiectasis With Nonpharmacological Airway Clearance: CHEST Expert Panel Report

cyclebreathingwithorwithouttheassistanceofpostural drainage; positive expiratory pressure (PEP);?utter-type devices; airway oscillation; respiratory muscle training; coached coughing; huf?ng; cough assist device (insuf?ation/exsuf?ation); assisted coughing (eg, quad coughing); functional electrical stimulation; high- frequency chest wall oscillators; and general exercise. The aims of treatment are to clear the airways of tenacious secretions, reduce cough and sputum production, improve functional and health status, and reduce the frequency (...) discovered while no newer primary studies were identi?edthroughthissearch(Fig 1). Using dual review, four panelists independently reviewed the titles and abstracts of the search results to identify potentially relevant articles based on the inclusion and exclusion criteria. Discrepancies were resolved by discussion. Studies deemed eligible then underwent a second round of full-text screening for ?nal inclusion. Important data from each included study were then extracted into structured evidence tables (e

2018 American College of Chest Physicians

18. All-Terrain Vehicle Injuries, Prevention of

, 2017 was conducted in July of 2017. In addition to the electronic search, manual review of bibliographies of articles and recent reviews was by the lead author (D.K.J.). Study Selection FIGURE 1. PRISMA flow diagram. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Two independent researchers (R.R., D.K.J.) screened titles and abstracts using the aforementioned inclusion and exclusion criteria. Any disagreement was adjudicated by a third, senior, GRADE-trained researcher (...) Association Trauma Committee position statement on the use of all-terrain vehicles by children and youth. J Pediatr Surg . 2009;44(8):1638–1639. Yanchar NL. Preventing injuries from all-terrain vehicles. Paediatr Child Health . 2012;17(9):513–514. American College of Emergency Physicians (ACEP). Motorized recreational vehicle and watercraft safety. Policy statement. Ann Emerg Med . 2013;61(6):725–726. Franklin RC, Knight S, Lower T. Mount Isa statement on quad bike safety. Rural Remote Health . 2014;14(3

2018 Eastern Association for the Surgery of Trauma

19. AliveCor Heart Monitor and AliveECG app for detecting atrial fibrillation

study found that opportunistic, community-based screening for undiagnosed AF, using the AliveCor Heart Monitor and the AliveECG app, was cost effective. The AliveCor Heart Monitor was rebranded as Kardia Mobile in October 2016. AliveCor Heart Monitor and Kardia Mobile are functionally identical. © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 32Product summary and lik Product summary and likely place in ther (...) to make ECG readings at any time. Cost and resource use Cost and resource use An AliveCor Heart Monitor unit costs £62.49, excluding VAT. The AliveECG app and the Provider Dashboard are free of charge. A health economic evaluation of community-based screening in Australia reported that the AliveCor system was cost effective in detecting AF and preventing stroke, with an ICER of £2799 when compared with standard diagnostic assessment for AF, which included consultation with a GP and a specialist

2015 National Institute for Health and Clinical Excellence - Advice

20. HTA of smoking cessation interventions

on individual smokers. The time horizon over which the costs and benefits of screening was calculated was 20 years and both costs and benefits were discounted at 5%. ? A budget impact analysis reporting the incremental costs associated with changes to the provision of smoking cessation services over a five-year time horizon was performed from the perspective of the public health system only. ? An analysis of the ethical, legal and organisational implications of changes to the provision of smoking cessation

2017 Health Information and Quality Authority

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>